Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavirenz/lamivudine/tenofovir disoproxil fumarate - Viatris

Drug Profile

Efavirenz/lamivudine/tenofovir disoproxil fumarate - Viatris

Alternative Names: 3TC/EFV/TDF; Avonza; Efavirenz 400mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz 600mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz/tenofovir disoproxil fumarate/lamivudine; EFV/3TC/TDF; EFV/TDF/3TC; Lamivudine/efavirenz/tenofovir disoproxil fumarate; Lamivudine/tenofovir disoproxil fumarate/efavirenz; Symfi; Symfi Lo; TDF/3TC/EFV; Telura; Tenofovir disoproxil fumarate/efavirenz/lamivudine; TLE 400

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Matrix Laboratories
  • Developer The HIV Netherlands Australia Thailand Research Collaboration; Viatris Inc
  • Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Mar 2018 Mylan intends to launch efavirenz/lamivudine/tenofovir disoproxil fumarate (600mg/300mg/300mg) in USA in second quarter of 2018
  • 22 Mar 2018 Registered for HIV-1 infections (In adolescents, In children, In adults) in USA (PO)
  • 02 Mar 2018 Mylan intends to launch efavirenz/lamivudine/tenofovir disoproxil fumarate in USA in March 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top